After successfully growing and steering the $582 million sale of Madison-based Third Wave Technologies, Kevin Conroy went looking for another company to run. He found Exact Sciences — a struggling, publicly traded Massachusetts company with a DNA-based test for colon cancer that hadn’t been approved by the Food & Drug Administration (FDA).